tag:blogger.com,1999:blog-9551150.post114332133117133418..comments2024-03-28T01:27:23.408-04:00Comments on Health Care Renewal: An Unrevealing Interview with Genentech's CEORoy M. Poses MDhttp://www.blogger.com/profile/00497209843184497847noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-9551150.post-1153933115357329392006-07-26T12:58:00.000-04:002006-07-26T12:58:00.000-04:00Thank you for caring enough to write your article,...Thank you for caring enough to write your article, however I want to address one part of it.<BR/><BR/>I am not addressing the cost of Avastin but rather I am addressing your comment about the CEOs salary. If he is trying to run a company that produces pharmaceuticals (for which research and trials cost alot), why should he not be compensated as the top person. We don't get concerned with CEO'sAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-9551150.post-1143347315949176672006-03-25T23:28:00.000-05:002006-03-25T23:28:00.000-05:00I have worked on pricing of new biotech therapeuti...I have worked on pricing of new biotech therapeutics, like Avastin. I agree with your sentiments, but am not surprised by the interview.<BR/><BR/>Arthur Levinson's argument is the party line now. Pharmaceuticals point to the relatively low share of health care costs drugs are responsible for, and ask why insurers and the government are balking at paying their price (capitalizing on residual HMOAnonymousnoreply@blogger.com